A study to test single and multiple doses of MER511 given to adults with Graves’ disease

2025-523823-23-00 Protocol MER511-1001 Human pharmacology (Phase I) - First administration to humans Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 7 sites · Protocol MER511-1001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Authorised, recruitment pending
Participants planned 100
Countries 1
Sites 7

Graves’ disease

Key facts

Sponsor
Merida Biosciences Inc.
Participant type
Patients
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Decision date (initial)
2026-05-22
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2025-523823-23-00
ClinicalTrials.gov
NCT07305818

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Graves’ disease

VersionLevelCodeTermSystem organ class
28.0 LLT 10065624 Graves-Basedow disease 10014698
26.0 PT 10018706 Graves´ disease 10014698

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Merida Biosciences Inc.

Sponsor organisation
Merida Biosciences Inc.
Address
500 Technology Square Floor 8
City
Cambridge
Postcode
02139-3521
Country
United States

Scientific contact point

Organisation
Merida Biosciences Inc.
Contact name
Merida Clinical Trials

Public contact point

Organisation
Merida Biosciences Inc.
Contact name
Merida Clinical Trials

Locations

1 EU/EEA country · 7 investigational sites

By country

CountryMS statusPlanned subjectsSites
Spain Authorised, recruitment pending 28 7
Rest of world
United Kingdom, United States
72

Investigational sites

Spain

7 sites · Authorised, recruitment pending
Area Sanitaria Da Coruna E Cee
Endocrinology, Lugar Jubias De Arriba Num 84, 15006, A Coruna
Hospital Quironsalud Barcelona
Endocrinology, Placa D'alfonso Comin 5-7, 08023, Barcelona
Micancer Center S.L.P.
Endocrinology, Calle Del Doctor Roux 76 Planta 5, 08017, Barcelona
Hospital Universitario Virgen De La Victoria
Endocrinology, Calle Del Arroyo Teatinos Sn, 29010, Malaga
Hospital Universitario Marques De Valdecilla
Endocrinology, Avenida Valdecilla Sn, 39008, Santander
Hospital Universitario Virgen De La Macarena
Ohptalmology, Avenida Del Doctor Fedriani 3, 41009, Sevilla
University Hospital Virgen Del Rocio S.L.
Endocrinology, Avenida De Manuel Siurot S/n, 41013, Sevilla

Application history

1 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2026-02-20 Spain Acceptable
2026-05-21
2026-05-22